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Abstract
Background: Acceleration of chronic diseases, particularly cardiovascular disease, may increase long-term mortality after
community-acquired pneumonia (CAP), but underlying mechanisms are unknown. Persistence of the prothrombotic state
that occurs during an acute infection may increase risk of subsequent atherothrombosis in patients with pre-existing
cardiovascular disease and increase subsequent risk of death. We hypothesized that circulating hemostasis markers
activated during CAP persist at hospital discharge, when patients appear to have recovered clinically, and are associated
with higher mortality, particularly due to cardiovascular causes.
Methods: In a cohort of survivors of CAP hospitalization from 28 US sites, we measured D-Dimer, thrombin-antithrombin
complexes [TAT], Factor IX, antithrombin, and plasminogen activator inhibitor-1 at hospital discharge, and determined 1-
year all-cause and cardiovascular mortality.
Results: Of 893 subjects, most did not have severe pneumonia (70.6% never developed severe sepsis) and only 13.4%
required intensive care unit admission. At discharge, 88.4% of subjects had normal vital signs and appeared to have
clinically recovered. D-dimer and TAT levels were elevated at discharge in 78.8% and 30.1% of all subjects, and in 51.3% and
25.3% of those without severe sepsis. Higher D-dimer and TAT levels were associated with higher risk of all-cause mortality
(range of hazard ratios were 1.66-1.17, p = 0.0001 and 1.46-1.04, p = 0.001 after adjusting for demographics and comorbid
illnesses) and cardiovascular mortality (p = 0.009 and 0.003 in competing risk analyses).
Conclusions: Elevations of TAT and D-dimer levels are common at hospital discharge in patients who appeared to have
recovered clinically from pneumonia and are associated with higher risk of subsequent deaths, particularly due to
cardiovascular disease.
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Introduction
It is well recognized that hospitalizations for community-
acquired pneumonia (CAP) are associated with high long-term
mortality, but underlying reasons are not known [1–6]. We and
others have shown that higher long-term mortality for CAP cannot
be solely explained by higher burden of chronic diseases prior to
the occurrence of infection [6–8]. Rather, CAP may accelerate
progression of pre-existing chronic diseases. For example, several
epidemiologic studies have shown that acute cardiovascular
events, including myocardial infarction [9–12], stroke [13], and
pulmonary thromboembolism [14], occur at a higher than
expected frequency following respiratory infections and are the
most common cause of death after CAP [3,6].
We recently proposed an alternative mechanism to explain the
epidemiologic link between infection and the higher risk of death,
particularly due to acute cardiovascular events [15]. Activation of
the host response to infection may persist at hospital discharge
when patients appeared to have recovered clinically from the
infection, and increase risk of acute deterioration of cardiovascular
disease and subsequent deaths. During an acute infection,
activation of the hemostatic system leads to a prothrombotic state
[16,17]. Recently we showed that these abnormalities are common
during less severe infection [16,17]. Atherothrombosis may occur
due to a prothrombotic state and lead to an acute cardiovascular
event and death [18]. Therefore, in a large, multicenter cohort of
survivors of CAP hospitalization we determined whether hemo-
static abnormalities activated during an acute infection persist
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during recovery and increase risk of subsequent all-cause and
cardiovascular deaths. We also assessed whether the association
between circulating hemostasis markers and death was indepen-
dent of previously reported association between increased
circulating inflammatory marker levels and higher mortality [15].
Methods
Ethics Statement
The Institutional Review Boards at the following hospitals
approved the study: Pennsylvania: Allegheny General Hospital,
Jefferson Hospital/SHHS, Mercy Hospital, St. Clair Memorial
Hospital, St. Francis Medical Center, Sewickley Valley Hospital,
University of Pittsburgh Medical Center (UPMC) Braddock,
UPMC Horizon, UPMC Lee, UPMC McKeesport, UPMC
Passavant, UPMC Presbyterian, UMPC Shadyside, UPMC
Southside, UPMC St. Margaret, West Penn Hospital; Connecti-
cut: Bridgeport Hospital, Hartford Hospital, Milford Hospital,
New Britain General Hospital, Norwalk Hospital, Yale-New
Haven Hospital; Tennessee: Methodist Health Care (single IRB
approval for three Methodist University sites); Michigan: Henry
Ford Health System, Detroit Receiving/Sinai-Grace, Wayne
State. Written, informed consent was obtained from all partici-
pants or by proxy.
Subjects and design
We conducted 1-year follow-up of all hospital survivors of the
Genetic and Inflammatory Markers of Sepsis (GenIMS) study
[19]. GenIMS is a large, multicenter observational cohort of
subjects with CAP presenting to the Emergency Departments
(EDs) of 28 teaching and non-teaching hospitals in the US. Eligible
patients were those older than 18 years of age with a diagnosis of
CAP based on clinical and radiological criteria, as described by
Fine et al [20]. Exclusion criteria included transfer from another
hospital, discharge from an acute care hospital within the previous
ten days, diagnosis of pneumonia within the previous 30 days,
chronic dependency on mechanical ventilation, cystic fibrosis,
active pulmonary tuberculosis, admission for palliative care, prior
enrollment in the study, incarceration, and pregnancy.
Clinical and outcome variables
We ascertained comorbid conditions using the Charlson
comorbidity index [21] and pre-existing cardiovascular disease
by patient report and chart review. APACHE III and the
Pneumonia Severity Index (PSI) were calculated to assess illness
severity [20,22]. We defined severe sepsis as pneumonia with acute
organ dysfunction following the 2001 International Consensus
Criteria [23,24]. We assessed vital signs at hospital discharge to
determine whether subjects met criteria for clinical stability at
hospital discharge, as described by Halm et al [25].
The primary outcome variables were all-cause and cardiovas-
cular (death due to acute myocardial infarction, ischemic or
atherosclerotic heart disease, and cerebrovascular disease) mortal-
ity 1 year after hospital discharge. We ascertained all-cause and
cause-specific mortality using the National Death Index (NDI)
search and NDI-coded causes of death [26]. The sensitivity and
specificity of NDI to assess deaths is .96% [27]. Causes of death
assessed by NDI matched causes of death assessed by nosologists in
.93% of cases in prior studies [28,29].
Laboratory procedures
We obtained blood daily for the first week and once weekly
thereafter, while subjects remained in hospital. For this study
we analyzed the last available hemostasis markers, including
antithrombin (AT), Factor IX, thrombin-antithrombin (TAT)
complexes, plasminogen activator inhibitor (PAI)-1, and D-dimer,
and inflammatory marker (interleukin [IL]-6).
We analyzed coagulation and fibrinolysis markers by a
commercial laboratory (Esoterix, Agoura Hills, CA, USA). Specific
methods and kits used were: D-dimer, latex immunoassay
(Diagnostica Stago, Parsippany, NJ, USA); PAI-1, bio immuno-
assay (Biopool Chromolize, Biopool International, Ventura, CA,
USA); AT, chromogenic (BioMerieux, Rhoˆne-Alpes, France);
Factor IX, clot (BioMerieux); and TAT, ELISA (Behring, King of
Prussia, PA, USA). Abnormal values were defined by the clinical
laboratory or manufacturer’s assay. These abnormalities included:
D-dimer .256 ng/ml, PAI-1 activity .31 IU/ml, antithrombin
activity ,70%, Factor IX activity ,60%, and TAT .5.0 ng/ml.
We measured IL-6 concentrations by chemiluminescent immuno-
assay using an automated analyzer (IMMULITE, Diagnostic
Products Corp., Los Angeles, CA, USA).
Statistical analyses
We first conducted univariate comparisons for subjects who
survived or died at 1 year. We assumed a log-normal distribution
for all markers and analyzed data in natural log scale. We assessed
the association between each marker and risk of death over 1 year
using the Gray’s survival model [30]. We used the Gray’s survival
models to estimate hazard ratios (HR) because the hazards failed
Cox’s proportionality assumption. The Gray’s model estimates
HR across 10 time intervals and provides a detailed description of
the change in hazard ratios over 1 year. We determined
unadjusted and adjusted HRs, adjusting for age, sex, race, and
Charlson score.
We conducted several sensitivity analyses. We analyzed the
subgroups that were less severely ill and most likely to have
recovered from the infection by analyzing those without severe
sepsis and those who were discharged home. Since pre-existing
cardiovascular disease is a potential confounder, we repeated the
analyses in the subset who did not report cardiovascular disease.
We assessed the association between each marker and
cardiovascular deaths, using a competing risk model because the
associations between these markers and different causes of death
are dependent and these risks compete with one another until a
subject dies due to a specific cause of death [31]. Previously, we
showed that inflammatory markers that are activated during the
acute infection remain elevated at hospital discharge [15], and
higher levels of IL-6 at discharge were associated with higher risk
of cardiovascular events. We therefore determined whether the
association between hemostasis markers and 1-year mortality were
independent of previously reported association between IL-6 and
1-year mortality.
Finally, we used logistic regression and calculated area under
curve (AUC) to evaluate the discriminatory ability of biomarkers
to predict long-term mortality and cardiovascular deaths. We
limited these analyses to biomarkers that were significant in the
multivariable analyses (IL-6 and D-dimer), and assessed AUC for
biomarkers alone and for biomarkers and pre-infection clinical
factors.
Results
Baseline characteristics and hospital course
Of the 2320 subjects enrolled in GenIMS, 291 patients were
excluded because they were discharged from the ED and another
134 were excluded because the clinical team ruled out CAP during
the first three days of hospitalization (Figure 1). Of the remaining
1895 subjects, hemostasis markers were measured in a random
Hemostasis Markers and Pneumonia Mortality
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subset of 939 consecutive subjects (49.5%). Of these, 46 (4.9%)
died in the hospital, and we conducted our analysis on 893 subjects
who were discharged alive.
Pre-hospitalization clinical characteristics, severity of illness, and
hospital course were similar for all subjects who were discharged
alive (n = 1799) and the subset (n = 893) who had hemostasis
markers measured at hospital discharge (Table 1). For the latter
group, the mean age of all subjects was 68.7 years, approximately
half were female, and two-thirds had at least 1 comorbid condition
based on the Charlson score. Pre-existing cardiovascular disease
was found in 201 (22.5%) subjects. Most subjects were non-
Hispanic whites (86.6%), an additional 94 (10.5%) subjects were
blacks, and the remaining 25 subjects represented other races. The
majority of subjects never required admission to the intensive care
unit (n = 773, 86.6%) and never developed severe sepsis (n = 631,
70.6%), and half (n = 417, 46.7%) of the subjects had a PSI score
less than 90 (PSI class I–III), suggesting that most subjects did not
have severe pneumonia. Mean hospital stay was 7 days. Three
quarters of subjects (n = 672, 75%) were discharged home and the
remaining were discharged to acute or sub-acute care facilities or
residential facilities.
Fifty-eight (6.4%), 94 (10.5%), and 148 (16.5%) subjects died by
90 days, six months, and 1 year, respectively. Of the 148 deaths
over 1 year, 33 (22.9%) were due to cardiovascular causes. Most
subjects who died due to cardiovascular causes did not report
history of cardiovascular disease (n = 20, 60.6% did not report pre-
existing cardiovascular disease).
Compared to 1-year survivors, non-survivors were older men
with at least 1 comorbid condition and they were more likely to
report cardiovascular disease prior to developing CAP (30.4% vs.
20.9%, P= 0.01, Table 1). Non-survivors had more severe CAP on
presentation, as evidenced by higher PSI and APACHE III scores,
were more likely to have developed severe sepsis, and incurred a
longer duration of hospital stay.
Hemostasis markers at hospital discharge
Most subjects met the Halm criteria for clinical stability on the
day of discharge. Only 15 (1.6%), 73 (8.1%), 24 (2.6%), and 8
(0.9%) subjects had a temperature greater than 37.8 C, heart rate
greater than 100/minute, respiratory rate greater than 24/minute,
or systolic blood pressure ,90 mm of Hg, respectively. All four
vital signs were normal in 789 (88.4%) subjects, 1 vital sign was
abnormal in 89 (9.9%) subjects, and only 15 (1.7%) subjects had
abnormalities in two or more vital signs.
Hemostasis markers were measured on the day of discharge in
523 (58.5%) subjects and most subjects (n = 805, 90.5%) had
hemostasis markers measured within 96 hours of discharge. For
Factor IX, AT, TAT, PAI-1, and D-dimer, the average circulating
concentrations (geometric means) at hospital discharge were
117.8%, 91.5%, 3.6 ng/ml, 3.8 IU/ml, and 598.3 ng/ml, respec-
tively (Table 2). Circulating TAT and D-dimer concentrations
were elevated in 30.1% and 78.8%, whereas levels had returned to
normal for most subjects for Factor IX, AT, and PAI-1 (7.9%,
10%, and 5% had abnormal levels).
The high frequency of elevated TAT and D-dimer levels at
hospital discharge were consistently observed across various
subgroups without severe pneumonia (Table 2). For example,
TAT and D-dimer levels were elevated in 25.3% and 51.3% of
subjects without severe sepsis and 23.5% and 49.4% of subjects
with less severe pneumonia (PSI class I–III). Furthermore, TAT
and D-dimer levels were elevated in 25.1% and 53.4% of subjects
who were discharged home from the hospital and likely to have
recovered from the acute infection.
Hemostasis markers and all-cause mortality
In univariate analyses, circulating concentrations of each
hemostasis marker at hospital discharge was associated with 1-
year survival. Table 3 and Figure 2 describes the range of HR over
ten time intervals for each hemostasis marker and risk of death
over 1 year. For example, the range of HRs for D-dimer was 1.6-
1.1 (p = 0.0001). The hazard of death for subjects with high D-
dimer levels were highest initially (HR=1.6 during the initial
week), decreased over time, and the HR was 1.1 during the last 3
months. A similar pattern was observed for TAT where higher
circulating levels was associated with higher 1-yr risk of death
(range= 1.49-1.1, p = 0.0001). The lower bounds of the 95% CI
for the hazard ratios remained above 1 for the first 111 days for
TAT and D-dimer. For PAI-1, the higher risk was observed only
during the initial 44 days. When adjusted for age, sex, race, and
Charlson score, higher circulating concentrations of TAT, PAI-1,
and D-dimer were associated with higher 1-year mortality
(Table 3). Figure 3 show failure plots for 25th and 75th percentile
of circulating TAT, D-dimer, and PAI-1 and survival over 1 year.
Consistent with prior results [15], higher concentrations of IL-6
were associated with higher risk of 1-year mortality (Table 3).
Figure 1. Subject disposition for the entire Genetic and
Inflammatory Markers of Sepsis (GenIMS) cohort. CAP indicates
community-acquired pneumonia.
doi:10.1371/journal.pone.0022847.g001
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Similar to the hemostasis markers, the hazard ratios were highest
at hospital discharge and decreased over time (adjusted range of
hazard ratios were 1.66-1.17, p = 0.0001, Figure 2 and 3). IL-6
concentrations significantly correlated with TAT and D-dimer
levels, but the magnitude of the correlation coefficients were
modest (Pearson coefficients for TAT and D-dimer with IL-6 were
0.16 and 0.32, p,0.0001 for both). The association between
higher TAT and D-dimer levels and 1-year mortality were
unchanged when adjusted for IL-6 levels at hospital discharge
(range of HR=1.4-1.01, p = 0.009 and 1.46-1.0, p = 0.008 for
TAT and D-dimer).
The presence of severe sepsis during hospitalization did not
influence the associations between each hemostasis markers and
1-year survival (interaction p value.0.05 for all markers, Table 4).
Table 1. Demographic and clinical characteristics.
All subjects discharged
alive (n=1799)
Subset with hemostatic
markers (n=893)
Subset with hemostatic markers
stratified by 1-year survival
Variable
Non survivors
(n =148)
Survivors
(n=745) P value
Demographics
Age, mean (sd, median) 67 (17, 71) 68.7 (15, 73) 76.5 (11, 78) 67.1 (16, 71) ,0.0001
Sex, female, n (%) 867 (48.2) 436 (48.8) 57 (38.5) 379 (50.8) 0.006
Race, white, n (%) 1443 (80.2) 774 (86.6) 132 (89.1) 642 (86.1) 0.32
Charlson comorbidity score.0 1297 (72.1) 616 (68.9) 123 (83.1) 493 (66.1) ,0.0001
Cardiovascular disease, n (%) 464 (29.1) 201 (22.5) 45 (30.4) 156 (20.9) 0.01
Severity of illness
Day 1 PSI*, mean (sd, median) 97 (36, 95) 95.5 (33, 93) 117.4 (32, 113) 91.1 (31, 90) ,0.0001
PSI Class I and II, n (%) 424 (23.6) 204 (22.9) 8 (5.4) 196 (26.3) ,0.0001
PSI Class III, n (%) 389 (21.6) 213 (23.9) 23 (15.5) 190 (25.5)
PSI Class IV, n (%) 663 (36.9) 340 (38) 69 (46.6) 271 (36.3)
PSI Class V, n (%) 323 (18.0) 136 (15.2) 48 (32.4) 88 (11.8)
Day 1 APACHE III score, mean (sd, median) 55 (17, 54) 55.8 (16, 55) 64.8 (15, 64) 53.9 (15, 53) ,0.0001
Severe sepsis, n (%) 498 (27.7) 262 (29.3) 71 (47.9) 191 (25.6) ,0.0001
Hospital course
Need for mechanical ventilation, n (%) 90 (5.0) 37 (4.1) 4 (2.7) 33 (4.4) 0.33
Required ICU stay, n (%) 250 (13.9) 120 (13.4) 19 (12.8) 101 (13.5) 0.81
Length of hospital stay, mean (sd, median) 7 (5,6) 7.2 (5, 6) 8.3 (5, 7) 7 (5, 6) 0.0001
Location following hospital discharge
Home, n (%) 1374 (77.5) 672 (75.3) 84 (56.8) 588 (78.9) ,0.0001
Acute or sub-acute care facility, n (%) 159 (9.0) 101 (11.3) 24 (16.2) 77 (10.3)
Residential care facilities, n (%) 43 (2.4) 101 (11.3) 36 (24.3) 65 (8.8)
Others, n (%) 6 (0.4) 19 (2.1) 4 (2.7) 15 (2)
*Based on Pneumonia severity index by Fine et al. [20].
doi:10.1371/journal.pone.0022847.t001
Table 2. Mean, median, interquartile range, and percentage of subjects with abnormal hemostasis marker levels at hospital
discharge.
Hemostasis markers
Geometric
mean
Median and
interquartile range Percentage with abnormal levels*
All subjects
(n=893)
Without severe sepsis
(n =631)
Discharged home
(n=672)
Factor IX (%) 117.8 129 (101, 158) 7.9 7.1 8
Antithrombin (%) 91.5 93 (80, 105) 10 8.8 8.3
TAT complexes (ng/ml) 3.6 3.3 (2.0, 5.9) 30.1 25.3 25.1
PAI-1 (IU/ml) 3.8 3.7 (1.0, 8.8) 5 5.3 5.2
D-dimer (ng/ml) 598.3 596 (298, 1210) 78.8 51.3 53.4
*Abnormal values were defined by the clinical laboratory or manufacturer’s assay. These abnormalities included: D-dimer .256 ng/ml, PAI-1 activity .31 IU/ml,
antithrombin activity ,70%, Factor IX activity ,60%, and TAT .5.0 ng/ml.
doi:10.1371/journal.pone.0022847.t002
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The hazard ratios for PAI-1, TAT, and D-dimer were similar in
subjects with and without severe sepsis but the confidence
intervals were wider. We also performed sensitivity analyses by
restricting the analyses to subjects with a hemostasis marker
measurement within 48 hours (n = 735), those discharged home
(n = 672), and those who did not report pre-existing cardiovas-
cular disease (n = 692). In these analyses, the hazard ratios
remained unchanged for the associations between TAT, D-
dimer, PAI-1, and IL-6 and reduced 1-year survival (Table 4),
though the association with mortality did not meet statistical
significance for some comparisons.
Hemostasis markers and cause-specific mortality
Cardiovascular disease and cancer were the most common
causes of death over 1 year and each accounted for approxi-
mately a fourth of all deaths (Table 5). Infections, renal failure,
and chronic respiratory disease accounted for 10.4% (n= 15),
7.6% (n= 11), and 14.5% (n = 21) of deaths, respectively. Table 5
Table 3. Hazard ratios* for association between circulating hemostasis markers at hospital discharge and all-cause mortality over 1
year.
Hemostasis markers Unadjusted hazard ratios P value Adjusted hazard ratios{ P value
Factor IX 0.56–0.74 0.005 0.68–0.94 0.23
Antithrombin 0.2–0.65 0.029 0.38–1.43 0.59
TAT complexes 1.1–1.49 0.0001 1.04–1.46 0.001
PAI-1 0.73–1.17 0.008 0.79–1.31 0.011
D-dimer 1.1–1.6 0.0001 1.07–1.55 0.0003
IL-6 1.21–1.68 ,0.0001 1.17–1.66 0.0001
*Range of hazards ratios are reported for ten time intervals over 1 year using the Gray’s model [30];
{Adjusted for age, race, sex, and Charlson score.
doi:10.1371/journal.pone.0022847.t003
Figure 2. Varying hazard ratios with 95% confidence intervals (CI) for circulating thrombin-antithrombin (TAT) complexes,
D-dimer, plasminogen activator inhibitor (PAI)-1, and interleukin (IL)-6 concentrations measured at hospital discharge and
mortality over 1 year. The hazard ratios are shown over ten time intervals based on the Grays’ model. For TAT, D-dimer, and IL-6, the lower bounds
of the CI are above 1 for the first 111 days. For PAI-1, the lower bounds of the 95% CI are above 1 for the first 44 days.
doi:10.1371/journal.pone.0022847.g002
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shows the geometric means for TAT, D-dimer, and PAI-1 for
each cause of death. Among subjects who died subsequently due
to cardiovascular disease, the D-dimer and TAT levels were
highest (1100.9 ng/ml and 5.5 ng/ml) and most had D-dimer
levels that were two-fold higher than levels seen in healthy
individuals (87.8% and 81.8% had D-dimer levels .256 ng/ml
and .512 ng/ml). In competing risk analyses, higher circulating
TAT and D-dimer concentrations at hospital discharge were
associated with deaths due to cardiovascular diseases (P = 0.003
and 0.009) but PAI-1 levels were not associated with cardiovas-
cular deaths (P = 0.30).
Biomarkers and predicting long-term mortality
Table 6 shows AUC for IL-6 and D-dimer to predict l-year all-
cause and cardiovascular mortality with and without clinical
factors. The discriminative ability of IL-6 and D-dimer was
modest (AUC=0.60 and 0.58 for 1-year mortality for IL-6 and
D-dimer) and AUC improved after adding clinical risk factors,
including age, sex, race, and Charlson comorbidity score
(AUC=0.72 for both IL-6 and D-dimer). Similar results were
observed for 1-year cardiovascular mortality, though D-dimer
had better discriminative ability (AUC=0.57 and 0.62 for IL-6
and D-dimer).
Discussion
In a large cohort of patients hospitalized with pneumonia, we
have shown that hemostasis markers are elevated during recovery,
as evidenced by higher TAT and D-dimer levels at hospital
discharge. At least a third and half of the cohort had higher TAT
and D-dimer levels at hospital discharge, even when analyses were
restricted to subjects who experienced less severe illness during the
hospital course or to those that appeared to have recovered
clinically and were discharged home from the hospital. Higher
concentrations of these hemostasis markers were associated with
higher risk of death over 1 year, particularly due to acute
deterioration of cardiovascular disease. These results were
independent of previously reported associations between inflam-
matory markers and cardiovascular deaths [15]. Our results
suggest that a persistent prothrombotic state after infection may
explain the epidemiologic link between infection and higher risk of
cardiovascular disease. Thus, interventions, such as aspirin and
statins, with beneficial effects on resolution of the prothrombotic
state and inflammation, should arguably be investigated to
improve long-term outcomes after pneumonia [32,33].
Our results are consistent with a previous animal study showing
that hemostasis markers are elevated after infection. In a mouse
Figure 3. Failure plots for high and low concentrations (25th and 75th percentiles of marker concentrations) of thrombin-
antithrombin (TAT) complexes, D-dimer, plasminogen activator inhibitor (PAI)-1, and interleukin (IL)-6 concentrations measured at
hospital discharge and mortality over 1 year. Using the Gray’s model, the hazard ratios are estimated at ten intervals over 1 year and hazard
ratios over five representative periods are shown. P values are obtained from the Grays’ survival model.
doi:10.1371/journal.pone.0022847.g003
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model of influenza, higher circulating concentrations of TAT
complexes, D-dimer, and PAI-1 persisted up to two weeks after the
infection [34]. Our results are also consistent with small
preliminary clinical studies [35–37]. For instance, higher hemo-
static marker concentrations have been reported during winter
months when the incidence of respiratory infections is high [35–
37]. Longitudinal analysis of hemostatic markers has been
performed in a small study of 54 subjects, where these markers
were measured prior to, during, and two weeks after a respiratory
tract infection and showed higher levels during recovery, but
results were not statistically significant [36].
Most individuals who died due to cardiovascular events in our
study did not have a prior history of cardiovascular disease. We
speculate that many subjects had sub-clinical cardiovascular
disease. Persistent inflammation and a pro-thrombotic state after
pneumonia may lead to activation of atherosclerotic plaque,
Table 4. Sensitivity analyses for association between circulating hemostasis marker concentrations at hospital discharge and
mortality over 1 year.
Hemostasis markers Adjusted hazard ratios{ P value
Subjects in whom hemostasis markers were measured within 48 hours (n = 735)
TAT complexes 1.04–1.41 0.022
PAI-1 0.9–1.42 0.091
D-dimer 1.07–1.64 0.0008
IL-6 1.26–1.81 ,0.0001
Subjects who did not report cardiovascular disease (n = 692)
TAT complexes 1.03–1.41 0.032
PAI-1 0.76–1.36 0.022
D-dimer 1.08–1.45 0.017
IL-6 1.24–1.74 0.0001
Subjects without severe sepsis (n = 631)
TAT complexes 0.94–1.3 0.39
PAI-1 0.86–1.37 0.14
D-dimer 0.97–1.55 0.023
IL-6 1.26–2.18 ,0.0001
Subjects with severe sepsis (n = 262)
TAT complexes 1.1–1.62 0.014
PAI-1 0.65–1.26 0.069
D-dimer 1.0–1.55 0.11
IL-6 0.9–1.12 0.86
Subjects discharged home (n = 672)
TAT complexes 1.02–1.21 0.59
PAI-1 0.77–1.33 0.12
D-dimer 0.89–1.43 0.18
IL-6 1.17–1.68 0.0017
*Range of hazards ratios are reported for ten intervals over 1 year using the Gray’s model [30];
{Adjusted for age, race, sex, and Charlson score.
doi:10.1371/journal.pone.0022847.t004
Table 5. Association between hemostasis markers at hospital discharge and cause-specific mortality over 1 year*.
Causes of death over 1 year %, (n) Geometric means of inflammatory markers at hospital discharge
TAT PAI-1 D-Dimer IL-6
Cardiovascular{ 22.3 (33) 5.5 3.5 1100.9 8.8
Infection{ 10.4 (15) 4.3 2.4 644.9 12.0
Cancer 29.8 (43) 4.2 2.8 912.5 14.5
Chronic lower respiratory disease 14.5 (21) 5.4 2.7 573.7 6.1
Renal failure 7.6 (11) 5.1 3.3 746.5 13.0
Others 9.7 (14) 4.5 4.2 880.3 8.3
{Cardiovascular causes of death include death due to acute myocardial infarction, ischemic or atherosclerotic heart disease, and cerebrovascular disease.
doi:10.1371/journal.pone.0022847.t005
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plaque rupture, and atherothrombosis, thereby precipitating an
acute cardiovascular event.
Higher levels of biomarkers on average were associated with
worse outcomes in our study, but biomarkers did not improve
discriminative ability to predict long-term outcomes. The lack of
improvement in discriminative ability could be due to the spread
of the biomarker values. The AUC for models incorporating
biomarkers and clinical risk factors was higher compared to
models that incorporated biomarkers alone, suggesting that
clinical factors may be important predictors. Additional studies
using different approaches, such as net reclassification index [38],
will be needed to understand the incremental value of measuring
biomarkers for different clinical risk groups. Our observations
provide important insights into a potential biologic link between
acute inflammation and subsequent death, but biomarkers may
not be useful clinical diagnostic tools.
In sensitivity analyses, we observed that hazard ratios for the
association between IL-6 and 1-year mortality were larger in the
subgroup without severe sepsis than among those with severe
sepsis. No interaction was observed between IL-6, severe sepsis
occurrence, and 1-year mortality. The clinical significance for
these intriguing findings is unclear. A potential explanation could
be that patients who have higher IL-6 concentrations but did not
meet clinical criteria for severe sepsis had more severe disease and
therefore associated with higher mortality.
In addition to deaths due to cardiovascular causes, deaths due to
cancer accounted for approximately a third of all deaths. Deaths
due to cancer may be increased in survivors of an acute infection
due to multiple reasons, including identification of co-existing
cancers during radiologic investigations to diagnose pneumonia,
inability to tolerate chemotherapeutic regimens due to decondi-
tioning during recovery, and progression of cancer due to
increased systemic inflammation. The latter may occur due to
genetic and epigenetic modifications of cells [39].
Our study has several strengths. First, we analyzed a large
cohort of subjects who were recruited from different sites. We
analyzed patients hospitalized for pneumonia because prior studies
have shown an association between respiratory tract infection and
increased risk of cardiovascular events [9–11]. Thus, our results
are less likely to be confounded by differences in nature of
infection. Second, higher TAT and D-dimer levels and their
association with mortality and cardiovascular disease were robust
across different subgroups, including those with less severe illness
and subjects who had recovered adequately to be discharged home
from the hospital. Most subjects had normal vital signs at hospital
discharge. Thus, our results are less likely to be confounded by
illness severity or due to ongoing organ dysfunction at hospital
discharge.
Our study has limitations. First, we assessed only fatal
cardiovascular events. Whether elevated hemostasis markers are
associated with non-fatal cardiovascular events after hospital
discharge is not known. Second, for practical reasons, we analyzed
a small number of hemostasis markers. We chose these markers
because they are activated during infection and were associated
with higher risk of cardiovascular events in prior studies [35,40].
Since subjects were recruited from several sites, we were unable to
measure platelet function to accurately assess the prothrombotic
state because these assays have to be performed promptly after
collecting a blood sample. Furthermore, other markers within the
coagulation pathway and markers of endothelial function may also
play an important role. Third, pre-infection levels of D-dimer were
not available in our study. However, in most subjects the D-dimer
levels were at least two-fold higher than the manufacturer’s upper
limit of normal and were four-fold higher among those who died
due to cardiovascular causes. Such high levels have been reported
in patients with suspected pulmonary thromboembolism and deep
venous thrombosis [41]. Thus, our results are unlikely to be
confounded by higher pre-infection levels.
In conclusion, our results suggest a mechanism to explain
increased long-term mortality after pneumonia hospitalization and
the well-described epidemiologic link between infection and
cardiovascular disease. A prothrombotic state is common at hospital
discharge in patients recovering after pneumonia hospitalization
and is associated with higher risk of all-cause mortality and
cardiovascular deaths over 1 year after hospital discharge.
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